Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC-01 in Major Depressive Disorder
NCT02046564Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Feb 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of aripiprazole in major depressive disorder (MDD), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Mean Change From Baseline in the Montgomery-Åsberg Depression Rating Scale Total Score at 6 weeks. Started Feb 2014; status: completed.
02
Drugs
aripiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02046564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02046564.